Results 241 to 250 of about 105,792 (367)

Serious Infections in Offspring Exposed to Tumor Necrosis Factor Inhibitors During Pregnancy: Comparison of Timing During Pregnancy and Placental Transfer Ability

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated serious infection risk in offspring exposed to tumor necrosis factor inhibitors (TNFi) in utero, separated by TNFi timing and placental transfer ability. Methods Using MarketScan (2011–2021), we identified offspring born to mothers with chronic inflammatory diseases.
Leah K. Flatman   +6 more
wiley   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich   +10 more
wiley   +1 more source

Measuring the Impact: MRI Response of Sacroiliac Joints to TNF Inhibitors in Youth with Axial Disease

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To evaluate the timeline for resolution of sacroiliac joint (SIJ) inflammation, changes in structural lesions, and their correlation with patient‐reported outcomes in youth with axial juvenile spondyloarthritis (axJSpA) initiating TNF inhibitor (TNFi).
Timothy G. Brandon   +8 more
wiley   +1 more source

Head Growth Trajectories During the First Year of Life and Risk of Autism Spectrum Disorder

open access: yesAutism Research, EarlyView.
ABSTRACT Atypical infant head circumference (HC)—including increased rates of macrocephaly and microcephaly—has been linked to autism spectrum disorder (ASD). However, specific head growth trajectories associated with ASD remain poorly defined. This retrospective case–control study aimed to delineate these trajectories and examine their relationship to
Rewaa Balaum   +7 more
wiley   +1 more source

Population pharmacokinetics and exposure–response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In the AEGEAN study, perioperative durvalumab plus platinum‐based neoadjuvant chemotherapy for patients with resectable stage II to IIIB (N2) non‐small‐cell lung cancer (NSCLC) demonstrated a favourable benefit–risk profile. This study evaluated population pharmacokinetics (PopPK) and exposure–response (ER) relationships of durvalumab in patients ...
Xiaoying Zhao   +12 more
wiley   +1 more source

Zulu ocular biometry differs fundamentally from that of Europeans - A modelling analysis. [PDF]

open access: yesOphthalmic Physiol Opt
Lockett-Ruiz V   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy